Tonight’s digest tracks a trillion-dollar retail coronation, a fragile geopolitical tariff truce, a pharma darling losing its halo, and crypto’s brutal reminder that liquidity rules all. Walmart’s transformation is real, India’s leverage play is bold but murky, Novo Nordisk’s stumble exposes execution risk, and Bitcoin’s slide confirms it’s trading like a high-beta asset, not digital gold. Big moves, bigger implications, and plenty of fine print still waiting to bite. Walmart hits $1 trillion market cap Walmart became the first traditional retailer to hit a $1 trillion market cap , crossing the mark Tuesday after its stock surged past $126 per share. The milestone underscores a dramatic transformation for a company that moved beyond discount retail into a tech-powered behemoth. E-commerce sales jumped 27% in the latest quarter, while advertising revenue rocketed 53%, offsetting thin brick-and-mortar margins. New CEO John Furner inherits a company firing on all cylinders: stock up 24% last year, 11% in 2026 alone, crushing the S&P 500. Using physical stores as delivery hubs beats Amazon’s model, plus a high-margin ad business rivaling Big Tech turned out to be Walmart’s secret weapon. India-US trade deal brings relief Trump slashed India’s tariff rate from 50% to 18%, a massive relief, though specifics remain fuzzy. Modi agreed to ditch Russian oil, instead buying American energy and committing to $500 billion in US goods purchases. The real catalyst however seems India’s EU mega-deal, termed as the “mother of all deals.” The deal gave Modi leverage to negotiate from strength, not desperation. Yet details are hazy. Will Modi actually halt Russian crude, or just trim imports? The timeline’s unclear. Analysts note 18% still hammers small US businesses, six times higher than 2024 rates. India’s stock market crashed last year on tariff fears; this deal provides breathing room but doesn’t erase geopolitical rifts. Washington wanted India’s oil pivot to pressure Putin on Ukraine. Modi’s got political cover now, but the fine print tells the real story, and it’s still being written. Novo slides on weak 2026 outlook Novo Nordisk dropped a bombshell: 2026 sales will plunge 5-13%, sending shares into a 15% freefall Tuesday. The pharma giant pointed at brutal US price cuts under Trump’s Most Favored Nation deal, plus patent cliffs in Canada, Brazil, and China killing exclusivity. Eli Lilly’s Mounjaro ate their lunch as it works better, gaining share faster while compounding pharmacies undercut Wegovy at half the price. New CEO Mike Doustdar’s banking on oral Wegovy’s January launch and CagriSema (the next-gen combo drug) to reverse the bleeding, but that’s a long shot against Lilly’s momentum. The real issue is that analysts expected 2% decline; Novo’s guiding toward double-digit pain. Stock down 46% last year. Investor confidence is shot. The comeback narrative hinges entirely on execution, and Novo’s stumbled too many times already. Bitcoin slips below $74,000 Bitcoin slipped below $74,000 on Tuesday, marking a nine-month low and 40% plunge from its $126,000 peak. The culprit isn’t Iran per se, it’s macro collapse: Fed uncertainty after leadership changes, real yields climbing, the dollar strengthening, and spot Bitcoin ETF outflows signaling institutional panic. Geopolitical jitters matter less when liquidity evaporates. Derivatives liquidations cascaded across weekend thin trading, wiping $5 billion in open positions. Iran tensions actually flash-crashed oil earlier in January when Trump threatened strikes, but higher crude killed safe-haven demand by crushing real returns. Bitcoin flipped from geopolitical hedge to leveraged risk asset . Support at $74,000 is critical as breaching it would provide bears with a new target $68,000. Until the Fed signals rate cuts or liquidations stabilize, crypto’s racing downwind. The post Evening digest: Walmart's $1T mark, Novo's weak outlook, Bitcoin slips below $74K appeared first on Invezz
